CJC-1295 (with DAC)
GHRH Analog (long-acting)Also known as: CJC-1295 DAC · Drug Affinity Complex CJC-1295
A GHRH analog modified with a Drug Affinity Complex that covalently binds albumin, extending half-life to 8–10 days. Produces continuous GH elevation rather than pulsatile release.
Typical Dose
1–2 mg once or twice weekly
Route
Subcutaneous injection
Cycle
8–16 weeks
Half-life
~8–10 days
Storage
Reconstituted: 2–8°C, use within 30 days.
Overview
CJC-1295 with DAC is derived from the same modified GHRH(1-29) sequence as CJC-1295 (no DAC) but with an additional Lys-maleimidopropionamide linker that enables covalent binding to circulating albumin. This extends its half-life to approximately 8–10 days versus 30 minutes for the no-DAC form.
The resulting pharmacokinetic profile is fundamentally different: instead of contributing to timed pulsatile GH release, CJC-1295 DAC produces a continuous, blunted elevation of GH output analogous to GH bleed rather than physiological pulsing. This reduces the peak-to-trough ratio that some users prefer, but allows once-weekly or twice-weekly dosing.
Some practitioners consider continuous GH elevation less physiological than pulsatile release & potentially more prone to IGF-1 side effects (water retention, insulin resistance) at high doses. Others prefer the convenience of less frequent injection. Both no-DAC & DAC versions are widely tested.
Quick Start Guide
Reconstitute with 2 mL bacteriostatic water per 2 mg vial.
Inject 1–2 mg subcutaneously once or twice per week.
Can be stacked with a GHRP (Ipamorelin, GHRP-2) at injection time to amplify each dose.
Research Indications
Sustained GH elevation (convenient dosing)
EffectiveMaintains elevated GH output throughout the week without daily injections. Preferred by users who prioritize convenience over pulse kinetics.
Body composition & anti-aging
EffectiveIGF-1 elevation & downstream anabolic/lipolytic effects. Similar endpoint to no-DAC but via continuous rather than pulsatile mechanism.
Research Protocols
Weekly GH support
8–16 weeksDose
1 mg once weekly + 200 mcg Ipamorelin at injection time
Frequency
Once weekly (CJC DAC) + 1–2x daily (Ipamorelin)
Route
SubQ abdomen
Twice-weekly dosing
8–16 weeksDose
1 mg 2x/week
Frequency
Twice weekly
Route
SubQ abdomen
Peptide Interactions
Adding a GHRP at each injection amplifies the GH response even on a long-acting GHRH. Compatible.
Both are GHRH analogs — no benefit to stacking them. Choose one based on dosing preference.
Side Effects & Safety
Common
- Water retention (more sustained than with no-DAC)
- Tingling or numbness in extremities
- Fatigue
Uncommon
- Joint pain (water retention)
- Headache
- Insulin resistance at high doses
When to Stop
- Known malignancy
- Signs of allergic reaction
- Diabetics: monitor glucose carefully given sustained GH elevation
How to Reconstitute
Wipe stopper.
2 mL bacteriostatic water per 2 mg vial.
Inject down inner wall. Swirl gently.
Refrigerate.
Dosing math: 1000 mcg/mL with 2 mL BAC water. For 1 mg: 1.0 mL. For 2 mg: 2.0 mL.
Quality Indicators
Good — use as normal
- Clear, colorless solution
Acceptable
- Very faint tint
Discard immediately
- Persistent cloudiness
- Particulate
- Discoloration
What to Expect
Week 1
GH elevation begins within 24 hours. Water retention often apparent by day 3–5.
Week 2–4
IGF-1 levels rising. Sleep quality & recovery improving.
Week 5–16
Sustained body composition improvements. Water retention typically stabilizes.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Research References
Long-acting growth hormone-releasing hormone analogs: clinical implications & preliminary results
Endocrine · 2003
Characterizes the DAC technology & its extension of GH-releasing activity across days.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample